Clinical Trials Browser

Phase 2 × Completed × selinexor × Clear all

NCT03992339 2025-02-07

SEARCH

Phase 2 Completed

60 enrolled 9 charts

Lymphoma, Large B-Cell, Diffuse

NCT06212596 2024-01-19

MUKtwelve

Phase 2 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT03944057 2023-06-15

MARCH

Phase 2 Completed

82 enrolled 9 charts

Multiple Myeloma, Recurrence

NCT02025985 2023-01-26

SIGN

Phase 2 Completed

116 enrolled 21 charts

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02088541 2023-01-26

SOPRA

Phase 2 Completed

317 enrolled 25 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02336815 2023-01-26

STORM

Phase 2 Completed

202 enrolled 30 charts 2 FDA

NCT02249091 2021-08-25

A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Phase 2 Completed

42 enrolled 16 charts

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT02402764 2020-09-11

Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)

Phase 2 Completed

10 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02250885 2019-09-17

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Phase 2 Completed

Carcinoma, Neuroendocrine